Mark J. Mendel

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Auxeris Therapeutics, Inc. manufactures drugs for osteoporosis, bone metastasis and other bone diseases. The company was founded in 2002 and is located in St. Louis, MO

CyDex Pharmaceuticals, Inc. provides pharmaceutical discovery, development and manufacturing services. Its product Captisol is a polyanionic beta-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether (SBE). The firm engages in technology with substantial characterization, safety documentation and regulatory review. The company was founded in 1990 and is headquartered in San Diego, CA.

Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA.

Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA.

Optobionics Corp. develops artificial retina and related devices to restore vision for individuals afflicted with retinitis pigmentosa, age-related macular degeneration, and other outer retinal diseases that can lead to blindness. It was founded by Alan Y. Chow and Vincent Y. Chow in 1990. The company is headquartered in Naperville, IL.

GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD.

Brookhaven National Laboratory provides research services. The firm conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies and national security. It also builds and operates scientific facilities available to university, industry, and government researchers. The company was founded in 1947 and is headquartered in Upton, NY.